Predicting response to immunotherapy in liver cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of a cytofluorimetric assay in predicting how patients with hepatocellular carcinoma (HCC) will respond to immunotherapy. It focuses on analyzing specific biomarkers in peripheral blood mononuclear cells (PBMC) to identify responders and non-responders early in the treatment process. The study will also investigate transcriptomic signatures to enhance the predictive accuracy of the assay. By comparing these biomarkers and signatures, the study seeks to improve treatment outcomes for HCC patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥ 18 years
* diagnosis of HCC
* execution of laboratory tests and subsequent treatments and follow-up at our center.
* obtained written informed consent to the study participation

Exclusion Criteria:

* immune-related concomitant diseases
* HIV infection

Where it's running

• IRCCS-Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Laura Gramantieri, Italy Recruiting

Study contacts

• Principal investigator: Laura Gramantieri — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Laura Gramantieri, MD
• Email: laura.gramantieri@aosp.bo.it
• Phone: 0512142579

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Next Generation Delivery System (NGDS) for SBRT in thorax and upper abdomen

  A study tests a new machine to deliver SBRT more quickly and comfortably for adults with thoracic or upper abdominal cancers.

  Recruiting at 2 sites Varian, a Siemens Healthineers Company · St Louis, Missouri and 1 other locations · NCT07824583

• Personalized exercise plan for cancer survivors

  This study tests a personalized, physician-guided exercise program for adults who have completed cancer treatment, to see if a safe, structured plan can be implemented in routine care.

  Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan · NCT07751783

• Radiation segmentectomy with Y-90 resin microspheres for liver tumors

  This will test whether injecting Y-90 resin microspheres into the tumor-bearing part of the liver is safe and can shrink tumors in adults with liver cancer.

  Recruiting at 9 sites Ankara University · Adana and 19 other locations · NCT07345247

• Personalized computer-guided planning for radioembolization in liver cancer

  This project will try using patient-specific computer models of liver blood flow to predict where radioactive microspheres go during transarterial radioembolization for people with hepatocellular carcinoma.

  Recruiting University Hospital, Ghent · Ghent · NCT07315633

• Adding angiotensin II to liver radioembolization to boost tumor radiation

  This trial will test whether a short intra-arterial infusion of angiotensin II given just before yttrium-90 radioembolization helps more radiation reach liver tumors and less reach healthy liver in adults with advanced or metastatic liver cancer.

  Recruiting Phase 2 UMC Utrecht · Utrecht, Utrecht · NCT07312292

• NIR‑II fluorescence guidance with ICG‑cisplatin nanoprobes for liver tumor resection

  This study tries a new ICG‑cisplatin nanoprobe injected through the liver artery to help surgeons see and remove single small hepatocellular carcinomas during laparoscopic anatomic hepatectomy.

  Recruiting Early Phase 1 West China Hospital · Chengdu, Sichuan · NCT07295262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.